Cargando…

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models

BACKGROUND: Scarce drug penetration in solid tumours is one of the possible causes of the limited efficacy of chemotherapy and is related to the altered tumour microenvironment. The abnormal tumour extracellular matrix (ECM) together with abnormal blood and lymphatic vessels, reactive stroma and inf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morosi, Lavinia, Meroni, Marina, Ubezio, Paolo, Fuso Nerini, Ilaria, Minoli, Lucia, Porcu, Luca, Panini, Nicolò, Colombo, Marika, Blouw, Barbara, Kang, David W., Davoli, Enrico, Zucchetti, Massimo, D’Incalci, Maurizio, Frapolli, Roberta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434701/ https://www.ncbi.nlm.nih.gov/pubmed/34507591 http://dx.doi.org/10.1186/s13046-021-02070-x

Ejemplares similares

Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging
por: Giordano, Silvia, et al.
Publicado: (2016)

Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
por: Morosi, Lavinia, et al.
Publicado: (2020)

Determination of Paclitaxel Distribution in Solid Tumors by Nano-Particle Assisted Laser Desorption Ionization Mass Spectrometry Imaging
por: Morosi, Lavinia, et al.
Publicado: (2013)

PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study
por: Seki, Tomohiro, et al.
Publicado: (2022)

3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors
por: Giordano, S., et al.
Publicado: (2016)

A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging
por: Giordano, Silvia, et al.
Publicado: (2017)

Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
por: Petrillo, Marco, et al.
Publicado: (2019)

Inhibition of tumor‐associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti‐PD‐1 therapy
por: Belgiovine, Cristina, et al.
Publicado: (2021)

Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer
por: Ansaloni, L, et al.
Publicado: (2015)

New activities for the anti-tumor agent trabectedin: taking two birds with one stone
por: D'Incalci, Maurizio, et al.
Publicado: (2013)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Pseudo-resistance to anticancer drugs
por: Davoli, Enrico, et al.
Publicado: (2022)

IDN 5390: an oral taxane candidate for protracted treatment schedules
por: Pratesi, G, et al.
Publicado: (2003)

A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma
por: Uboldi, Sarah, et al.
Publicado: (2012)

Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice
por: Digifico, Elisabeth, et al.
Publicado: (2020)

Modulation of Bleomycin-Induced Lung Fibrosis by Pegylated Hyaluronidase and Dopamine Receptor Antagonist in Mice
por: Skurikhin, Evgenii Germanovich, et al.
Publicado: (2015)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Mitozolomide activity on human cancer cells in vitro.
por: Erba, E., et al.
Publicado: (1986)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Flow cytometric analysis of DNA content in human ovarian cancers.
por: Erba, E., et al.
Publicado: (1989)

Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
por: Colombo, T., et al.
Publicado: (1996)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018)

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
por: Vázquez, Ramiro, et al.
Publicado: (2016)

Tumor Response to Stroma-Modifying Therapy: Magnetic Resonance Imaging Findings in Early-Phase Clinical Trials of Pegvorhyaluronidase alpha (PEGPH20)
por: Arias-Lorza, Andrés M., et al.
Publicado: (2023)

Bioreducible Hydrophobin-Stabilized Supraparticles for Selective Intracellular Release
por: Maiolo, Daniele, et al.
Publicado: (2017)

THE INTERACTIONS OF THE NON-SPECIFIC INHIBITOR OF HYALURONIDASE WITH HYALURONIDASE AND PROTEOLYTIC ENZYMES IN VIVO
por: Hadidian, Z., et al.
Publicado: (1955)

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
por: Ko, Andrew H, et al.
Publicado: (2023)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
por: Zambelli, Alberto, et al.
Publicado: (2023)

Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
por: Rulli, Eliana, et al.
Publicado: (2018)

Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics
por: Fuso Nerini, Ilaria, et al.
Publicado: (2016)

Hyaluronidases in Human Diseases
por: Kaul, Aditya, et al.
Publicado: (2021)

Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine
por: Erba, E, et al.
Publicado: (2002)

Development of Folate-Functionalized PEGylated Zein Nanoparticles for Ligand-Directed Delivery of Paclitaxel
por: Soe, Zar Chi, et al.
Publicado: (2019)

PEGylated Paclitaxel Nanomedicine Meets 3D Confinement: Cytotoxicity and Cell Behaviors
por: Lin, Wenhai, et al.
Publicado: (2023)

The Adrenal-Hyaluronidase Relationship in Infection
por: Smith, Geo. H., et al.
Publicado: (1951)

THE REACTIVATION OF HEAT-INACTIVATED HYALURONIDASE
por: Emmart, E. W., et al.
Publicado: (1954)

HYALURONIDASES OF BACTERIAL AND ANIMAL ORIGIN
por: Meyer, Karl, et al.
Publicado: (1941)

Involvement of hyaluronidases in colorectal cancer
por: Bouga, Helen, et al.
Publicado: (2010)

Hyaluronidase sensitivity: Our experience
por: Mayor, Rahul, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fp8temfphfrovreo0o24616l57